论文部分内容阅读
目的:评价马来酸曲美布汀与谷维素对腹泻型患者伴肠易激综合征的临床疗效。方法:选取2014年8月—2016年8月期间收治的腹泻型肠易激综合征患者200例临床资料,按照随机序贯法将患者分为对照组和观察组,每组100例;对照组给予马来酸曲美布汀治疗,观察组在对照组基础上加用谷维素治疗,评价两组患者治疗后的总有效率和安全性。结果:观察组患者治疗后的总有效率为92.00%高于对照组为77.00%(P<0.05);两组患者用药期间不良反应的发生率经组间比较其差异无统计学意义(P>0.05)。结论:采用马来酸曲美布汀与谷维素联用治疗腹泻型患者伴肠易激综合征的疗效较为满意,用药期间不良反应的发生率较低。
Objective: To evaluate the clinical efficacy of trimebutine maleate and oryzanol in patients with diarrhea with irritable bowel syndrome. Methods: The clinical data of 200 patients with diarrhea-predominant irritable bowel syndrome admitted between August 2014 and August 2016 were selected. Patients were divided into control group and observation group according to randomized sequential method, with 100 cases in each group. The control group Trimebutine maleate treatment, the observation group on the basis of the control group plus oryzanol treatment, evaluation of the two groups of patients after treatment, the total efficiency and safety. Results: The total effective rate after treatment in the observation group was 92.00%, which was significantly higher than that in the control group (77.00%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Trimebutine maleate and oryzanol in combination with diarrhea patients with irritable bowel syndrome is more satisfied with the treatment of adverse reactions during the lower incidence.